Le nouveau monde des publications... https://t.co/AswIut30qa
RT @Fraslin: Données préliminaires recueillies auprès de 21 patients atteints de SDRA SRAS-CoV-2 et traités par tocilizumab (anticorps mon…
Et toujours aucune trace de l’étude de l’ @APHP
Données préliminaires recueillies auprès de 21 patients atteints de SDRA SRAS-CoV-2 et traités par tocilizumab (anticorps monoclonal qui bloque l’action des récepteurs de l’interleukine 6). https://t.co/ZRi3BfgF9O
RT @M35Blue: #TILS https://t.co/MbL756cBs6 The features of TZLS-501 consisting of its dual mechanism of action to inhibit signaling by th…
RT @M35Blue: #TILS https://t.co/MbL756cBs6 The features of TZLS-501 consisting of its dual mechanism of action to inhibit signaling by th…
RT @M35Blue: #TILS https://t.co/MbL756cBs6 The features of TZLS-501 consisting of its dual mechanism of action to inhibit signaling by th…
It has been recognised that the pro-inflammatory cytokine IL-6 plays a key role in cytokine release syndrome providing us with a potential target for immunotherapy. (See Buonaguro's editorial https://t.co/aQq7k8rTGD). 2/6 #pathology #pathophysiology #COV
#TILS https://t.co/MbL756cBs6 The features of TZLS-501 consisting of its dual mechanism of action to inhibit signaling by the membrane-bound and soluble IL-6 receptors along with rapid depletion of circulating IL-6 cytokine, a major cause of lung damage,
Core Pubmed: Anti-IL6R role in treatment of COVID-19-related ARDS.: Related Articles Anti-IL6R role in treatment of COVID-19-related ARDS. J Transl Med. 2020 04 14;18(1):165 Authors: Buonaguro FM, Puzanov I, Ascierto PA… https://t.co/DUsSAuE2Z0 #coronavir
RT @tango_ballet: COVIDに対するIL-6阻害薬の話に関しては, トシリズマブ(アクテムラ)以外に, サリルマブ (ケブザラ)の臨床試験結果も今後でてきそうですね. https://t.co/yaBb9gqRzf
COVIDに対するIL-6阻害薬の話に関しては, トシリズマブ(アクテムラ)以外に, サリルマブ (ケブザラ)の臨床試験結果も今後でてきそうですね. https://t.co/yaBb9gqRzf